Aurora Investment Counsel Acquires New Stake in Gilead Sciences, Inc. (GILD)
Aurora Investment Counsel acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 17,083 shares of the biopharmaceutical company’s stock, valued at approximately $1,224,000.
Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Welch Investments LLC acquired a new position in Gilead Sciences in the third quarter worth about $108,000. Wealthcare Advisory Partners LLC acquired a new position in Gilead Sciences in the third quarter worth about $133,000. Horan Capital Advisors LLC. acquired a new position in Gilead Sciences in the third quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Gilead Sciences in the second quarter worth about $147,000. Finally, Hanson & Doremus Investment Management raised its position in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (GILD) opened at $80.79 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The firm has a market cap of $105,510.00, a P/E ratio of 23.22, a P/E/G ratio of -1.77 and a beta of 1.22. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.
Several research analysts recently issued reports on GILD shares. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BMO Capital Markets reissued a “hold” rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Friday, October 20th. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $88.80 to $76.00 in a research report on Tuesday, January 30th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research report on Wednesday, January 17th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $87.04.
In related news, Director Gayle E. Wilson sold 60,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $77.92, for a total value of $4,675,200.00. Following the transaction, the director now directly owns 182,258 shares in the company, valued at $14,201,543.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 418,333 shares of company stock worth $32,742,108 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Aurora Investment Counsel Acquires New Stake in Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/aurora-investment-counsel-acquires-new-stake-in-gilead-sciences-inc-gild/1864760.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.